阿布昔替尼片一次能囤几盒?

Abxitinib tablets are a drug developed by Pfizer of the United States for patients with moderate to severe atopic dermatitis in adults and adolescents aged 12 years and above who have insufficient response or intolerance to existing systemic treatments (including biological agents). This article will introduce relevant information about Abxitinib tablets from three aspects: drug hoarding quantity, treatment needs and medication for special groups, to help patients plan their medication rationally.

How many boxes of Abxitinib tablets can be stocked at a time?

The stocking quantity must be considered based on the patient's specific medication needs and the drug's validity period. Each box of the drug has a specification of 100mg*14 tablets/box, and the validity period is usually 36 months, providing patients with a longer storage time.

Drug Validity Period and Storage Conditions

The validity period of Abxitinib tablets is usually 36 months. The storage conditions require sealing and the temperature not exceeding 30°C. If the storage conditions are met, patients can hoard medicines appropriately according to their own medication needs, but care must be taken to avoid drug expiration due to excessive hoarding.

Recommended stocking quantity

For patients who take medicine for a long time, it is recommended to stock up on 3-6 months’ worth of medication at a time, that is, about 6-12 boxes. This quantity can not only meet the needs of continuous treatment, but also avoid waste caused by excessive hoarding. For patients on short-term medication or during the dose adjustment period, it is recommended to purchase according to actual needs and avoid hoarding.

Reasonable stocking of Abxitinib tablets can not only ensure the continuity of treatment, but also reduce drug waste. Patients should flexibly adjust according to their own conditions.

How many boxes of Abxitinib tablets are needed in one treatment course

The number of treatment boxes of Abxitinib tablets depends on the patient’s treatment plan and dosage. The usual recommended dose is 100 mg once a day, but some patients may need to adjust to 200 mg once a day.

Calculation of conventional dose treatment course

Based on the dosage of 100 mg once a day, the patient takes 1 tablet per day, and each box of 14 tablets can meet the medication needs for two weeks. A standard 12-week course of treatment requires approximately 6 boxes of medicines. If the dose is adjusted to 200 mg once daily, 12 boxes will be required for a 12-week course of treatment.

Treatment requirements for special treatment plans

For patients who need to start treatment with 200 mg once a day for 12 weeks and then adjust the dose, 12 boxes are required in the first 12 weeks. Subsequent maintenance treatment is calculated at 100 mg once a day, which is about 2 boxes per month. Patients should calculate their total needs based on their doctor's specific treatment plan.

The number of treatment boxes of Abxitinib tablets needs to be determined according to the individualized treatment plan. Patients should fully communicate with their doctors before planning the quantity of medicines to purchase.

Usage of Abxitinib Tablets in Special Populations

There are differences in the dosage regimens of Absitinib Tablets in different populations, and special attention should be paid to dosage adjustment for special populations.

Usage in elderly patients

When elderly patients aged 65 and above use Abxitinib tablets, platelet count and lymphocyte count need to be closely monitored. Clinical data shows that elderly patients are more likely to experience adverse reactions such as thrombocytopenia and herpes zoster, and it is recommended to start with a low dose and strengthen monitoring.

Usage in patients with liver and kidney dysfunction

Patients with moderate renal impairment need to reduce the dose, and patients with severe renal impairment are not recommended to use it. No dose adjustment is required in patients with mild or moderate hepatic impairment, but use should be avoided in patients with severe hepatic impairment. Liver and kidney function indicators need to be monitored regularly during medication.

Use by pregnant and lactating women

Pregnant and lactating women should be cautious when using Abxitinib tablets. Existing data are insufficient to assess its safety to the fetus. Breastfeeding women should stop breastfeeding during treatment and within one day after the last dose. Women of childbearing potential should be aware of the possible effects of medications on their fertility.

Special groups must strictly follow the doctor’s instructions when using Abxitinib tablets, and adjust the medication plan according to individual conditions.